PREP Workshop # 20: Investigational Drug Accountability. Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS
|
|
- Susanna Cannon
- 6 years ago
- Views:
Transcription
1 PREP Workshop # 20: Investigational Drug Accountability Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS
2 CME Disclosure Statement The North Shore LIJ Health System adheres to the ACCME s new Standards for Commercial Support. Any individuals in a position to control the content of a CME activity, including faculty, planners, and managers, are required to disclose all financial relationships with commercial interests. All identified potential conflicts of interest are thoroughly vetted by the North Shore-LIJ for fair balance and scientific objectivity and to ensure appropriateness of patient care recommendations. Course Director and Course Planner, Kevin Tracey, MD and Tina Chuck, MPH have nothing to disclose. Ji-Eun Kim has nothing to disclose.
3 OBJECTIVES To review regulatory requirements and discuss best practices for drug accountability record and related documentation Regulatory Requirements Best Practices Investigational Drug Accountability
4 DRUG ACCOUNTABILITY RECORDS Auditable trail of drug management Receipt Preparation Dispensation Inventory Transfer Distribution Subject Return Return to Sponsor On-site Disposal
5 REGULATIONS & STANDARDS
6 FEDERAL REGULATIONS General responsibilities of investigators An investigator is responsible for.. the control of drugs under investigation Investigator recordkeeping and record retention An investigator is required to maintain adequate records of the disposition of the drug, including dates, quantity and use by subjects. <CFR Title 21 Section 312>
7 <E6 GCP: 4. Investigator and 5. Sponsor > GCP STANDARDS Responsibility for IP (Investigational Product) accountability at each site Delegation of duties for IP accountability to and supervision of an appropriately qualified person Maintaining documentation of IP management Delivery Inventory Dispensation Return to sponsor or on-site disposal Monitor's responsibilities
8 DRUG ACCOUNTABILITY RECORDS Authorized Subjects Authorized Prescribers DARF Compliance with Protocol Compliance with Regulations
9 FDA AND ORC AUDITS Drug Accountability Record Form: Absent, partial, incomplete and discrepant MISSING RECORDS No retrieval No destruction DISCREPANCY Source documents Actual inventory PRACTICES No scheduled verification No access by back-up staff
10 LESSONS FROM AUDITS Absent, incomplete, inaccurate and discrepant DARF: Not acceptable data Correct and reconcile Provide sufficient explanations on records Establish and implement procedures (e.g., staff trainings, scheduled inventory verification)
11
12 Study-specific Subject-specific NCI ACTG IPC or HRPP
13 Separate DARF Sheets Each Study Same Study Same PI Each drug Each dosage form Each drug strength Each lot number Each location
14 Contents Receipt Dispensation Distribution or transfer Periodic inventory verification Subject return Return to sponsor On-site disposal
15 Study Information North Shore-LIJ Health System Investigational Drug/Biologic Accountability Record Name of Hospital or Center: NSUH Protocol Title: A double-blinded ABC Study Dispensing Area or Pharmacy: NSUH Pharmacy IRB Number: A PAGE No. Investigator Name: Dr. Jones Investigator and/or Site Number: 06 Investigational Drug/Biologic Name: Dosage Form and Strength: Package Size: Inventory Unit: Storage Temperature: 1 Line No. Date Subject Initials Subject ID No. Dose Quantity Dispensed /Received Balance Forward Lot/Kit Number Expiration Date Recorder Initials Comments
16 Drug Information North Shore-LIJ Health System Investigational Drug/Biologic Accountability Record Name of Hospital or Center: NSUH Protocol Title: A double-blinded ABC Study Line No Date Subject Initials Subject ID No. Dose Quantity Dispensed /Received Dispensing Area or Pharmacy: NSUH Pharmacy IRB Number: A Balance Forward Lot/Kit Number Expiration Date PAGE No. 1 Investigator Name: Dr. Jones Investigator and/or Site Number: 06 Investigational Drug/Biologic Name: Healept Package Size: 60 tablets/bottle Inventory Unit: Bottle Dosage Form and Strength: Oral Tablet 100 mg Storage Temperature: C (68-77 F) Recorder Initials Comments
17 Receipt North Shore-LIJ Health System Investigational Drug/Biologic Accountability Record Name of Hospital or Center: NSUH Protocol Title: A double-blinded ABC Study Dispensing Area or Pharmacy: NSUH Pharmacy IRB Number: A PAGE No. 1 Investigator Name: Dr. Jones Investigator and/or Site Number: 06 Investigational Drug/Biologic Name: Healept Package Size: 60 tablets/bottle Line No. Date Subject Initials Subject ID No. Inventory Unit: Bottle Dose Quantity Dispensed /Received Dosage Form and Strength: Oral Tablet 100 mg Balance Forward Lot/Kit Number Storage Temperature: C (68-77 F) Expiration Date Recorder Initials 1 4/30/14 Received A1234 6/30/16 JK Comments
18 Dispensation North Shore-LIJ Health System Investigational Drug/Biologic Accountability Record Name of Hospital or Center: NSUH Protocol Title: A double-blinded ABC Study Dispensing Area or Pharmacy: NSUH Pharmacy IRB Number: A PAGE No. 1 Investigator Name: Dr. Jones Investigator and/or Site Number: 06 Investigational Drug/Biologic Name: Healept Package Size: 60 tablets/bottle Line No. Date Subject Initials Subject ID No. Inventory Unit: Bottle Dose Quantity Dispensed /Received Dosage Form and Strength: Oral Tablet 100 mg Balance Forward Lot/Kit Number Storage Temperature: C (68-77 F) Expiration Date Recorder Initials 1 4/30/14 Received A1234 6/30/16 JK 2 5/15/14 JD A13 2 Tabs BID A1234 6/30/16 JK 3 4 Comments
19 Scheduled Periodic Inventory Verification North Shore-LIJ Health System Investigational Drug/Biologic Accountability Record Name of Hospital or Center: NSUH Protocol Title: A double-blinded ABC Study Dispensing Area or Pharmacy: NSUH Pharmacy IRB Number: A PAGE No. 1 Investigator Name: Dr. Jones Investigator and/or Site Number: 06 Investigational Drug/Biologic Name: Healept Package Size: 60 tablets/bottle Line No. Date Subject Initials Subject ID No. Inventory Unit: Bottle Dose Quantity Dispensed /Received Dosage Form and Strength: Oral Tablet 100 mg Balance Forward Lot/Kit Number Storage Temperature: C (68-77 F) Expiration Date Recorder Initials 1 4/30/14 Received A1234 6/30/16 JK 2 5/15/14 JD A13 2 Tabs BID A1234 6/30/16 JK 3 6/1/14 Monthly Inventory 18 A1234 6/30/16 JK 4 Comments
20 Disposal North Shore-LIJ Health System Investigational Drug/Biologic Accountability Record Name of Hospital or Center: NSUH Protocol Title: A double-blinded ABC Study Line No. Date Subject Initials Subject ID No. Dose Quantity Dispensed /Received Dispensing Area or Pharmacy: NSUH Pharmacy IRB Number: A Balance Forward Lot/Kit Number Expiration Date Recorder Initials 1 4/30/14 Received A1234 6/30/16 JK 2 5/15/14 JD A13 2 Tabs BID A1234 6/30/16 JK 3 6/1/14 Monthly Inventory 18 A1234 6/30/16 JK 4 6/30/16 Destroyed on site A1234 6/30/16 JK PAGE No. 1 Investigator Name: Dr. Jones Investigator and/or Site Number: 06 Investigational Drug/Biologic Name: Healept Package Size: 60 tablets/bottle Inventory Unit: Bottle Dosage Form and Strength: Oral Tablet 100 mg Storage Temperature: C (68-77 F) Comments
21 Incorrect DARF entries should be crossed out with a single line and corrected with the date and the initials of the recorder. No erasure or white-out is allowed. Schedule periodic inventory verification to reconcile any discrepancies, secure sufficient supplies for upcoming subject visits and dispose of any expired drugs. Provide written explanations on any issues, if necessary, and retain them in the binder.
22 Activities DARF: Look and Find (Individual activity) There are 4 inappropriate records and practices on the form.
23 Activities Record of Drug Receipt (Group activity) Each bag contains drug supply for your team. First, discuss whether you need separate drug accountability record sheets to enter the receipt of your drug supply. One person in your team documents the receipt of the drugs on the provided form. Another person verifies the record.
24 Activities Discussion: Investigational Drug Accountability (Group activity) Each team will discuss 2 cases.
25 DOCUMENTATION Packing slip and invoice Receipt or delivery confirmation Temperature records during transit Signed informed consent forms Treatment arm and dose assignments Kit, bottle or vial assignments Prescriptions and drug orders Study-specific forms Administration records Subject return records Written approval from the sponsor Return to sponsor or on-site disposal records
26 TOOLS AND GUIDANCE Feinstein Institute for Medical Research Home For Professionals» Resources for Investigators» Clinical Research Service» Investigational Pharmacy Core» Tools and Guidance Tools for Investigational Drug Management Frequently Asked Questions Templates
27 CONTACT INFORMATION Ji-Eun Kim, RPh, PhD Research Pharmacist Investigational Pharmacy Core, CRS TEL:
TITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17
SOP #: INV-100 Page: 1 of 5 1. POLICY STATEMENT: DF/HCC research pharmacies follow a standard set of policy requirements for clinical trials. 2. BACKGROUND: None 3. RESPONSIBLE PERSONNEL: 3.1. Research
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More information10/17/2016. Learning Objectives. What is Drug Accountability. Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP
PREPARATION FOR DRUG MANAGEMENT AND ACCOUNTABILITY IN A CTN CLINICAL TRIAL Presented by Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationIND Drug Log Guidelines
9/24/2009 IND Drug Log Guidelines 1) An NCI DARF (Drug Accountability Record Form) should be kept on each strength of investigational drug. An investigational drug is considered to be any drug (including
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationINVESTIGATIONAL DRUG SERVICE (IDS) Standard Operating Procedures
INVESTIGATIONAL DRUG SERVICE (IDS) Standard Operating Procedures The Investigational Drug Service (IDS) strives to meet or exceed the standards of Good Clinical Practice (GCP). 1. UC Davis Health (UCDH)
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationDocument Number: SOP IV Original SOP: March 2010 Revision Number: mjb SOP IV: Transport to Satellite Pharmacies Effective Date: April 2013
S.O.P. IV TRANSPORT of Study Medications to Satellite Pharmacies I. PURPOSE A. To clarify the responsibilities and procedures of the Investigational Pharmacy in the transportation of study medications
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationPreparing for Close-Out of Studies and Sites
Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More informationGUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH MICHIGAN STATE UNIVERSITY ENVIRONMENTAL HEALTH AND SAFETY
GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH MICHIGAN STATE UNIVERSITY ENVIRONMENTAL HEALTH AND SAFETY REVISION 4.2018 INTRODUCTION In conducting research with controlled substances, University
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationMulti-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18
Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares
More informationComplexity of Retention Samples Selection in non-traditional Bioequivalence studies
Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Nageshwar R Thudi Ph.D. Director-Clinical R&D Teva Pharmaceuticals Disclaimer The views expressed herein are the views
More informationBRIEFING 1168 Compounding for Phase I Investigational Studies,
BRIEFING 1168 Compounding for Phase I Investigational Studies, PF 39(5) [Sept. Oct. 2013]. The current proposed chapter in PF 43(3) [May June 2017] is posted online at www.usp.org/usp-nf/notices/compounding-forphase-i-investigational-studies
More informationHuman Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance
Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationRETURNED MEDICATIONS AND RECLAMATION PROCESSING
Page 1 of 14 SUBJECT: PURPOSE: POLICY: Returned medications and reclamation processing To define the process for handling products returned to the Pharmacy to ensure that medications are properly destroyed
More informationNational Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services
National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services The Division of Microbiology and Infectious Diseases (DMID), National Institute
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationHuman Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationInvestigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
More informationOREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018
OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE OPERATING PROCEDURES Updated: March 2018 MISSION: To encourage safe, effective, and innovative drug policies that promote high
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationMAIMONIDES MEDICAL CENTER
MAIMONIDES MEDICAL CENTER CODE: AD-088 (Revised) ORIGINALLY ISSUED: October 2, 1990 SUBJECT: Product Safety Recall and Alert I POLICY In the event of a product safety recall or alert of a medical device
More informationAssessing the management of anti-tb medicines and supplies
Assessing the management of anti-tb medicines and supplies Management of anti-tb medicines and supplies Objectives: at the end of the assessment reviewers should comment on the availability of anti-tb
More informationStandard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
More informationEAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS
EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS JUNE 2012 (UPDATED FROM 2007 & 2010 STATEMENTS) What is meant by barcoding of the single dose? By single dose EAHP
More information10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.
Wednesday October 10, 2012 Please be sure to sign in and take copies of each handout. 1 Alicia Joy, IRB 2 FH Office of Research Administration Christina Jackson, BSN, RN, CCRC, CHRC 1 ClinicalTrials.gov
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationINVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)
INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationPreparing for a United States Food and Drug Administration (FDA) Inspection: VOICE
Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute
More informationSTANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA
STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA SOP#: 014.5 Date Issued: 11/00 Date Revised: 8/15 Page 1 of 5 TITLE: SCOPE: RESPONSIBILITY: PURPOSE: Research
More informationObtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process
Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process Helene Orescan, J.D. Bishoy Anastasi, MBA, CCRP David Geffen School of Medicine at UCLA Industry Sponsored
More informationBEST PRACTICES IN IRT IMPLEMENTATION:
BEST PRACTICES IN IRT IMPLEMENTATION: A PRIMER FOR APAC ARTICLE www.almacgroup.com By Matt Do, Client Development Lead, Asia Almac IN 2013, 16% OF CLINICAL TRIALS WERE CONDUCTED IN APAC, AND THAT PERCENTAGE
More informationBD Cato. medication workflow solutions. Elevating the standard of IV compounding
BD Cato medication workflow solutions Elevating the standard of IV compounding The current state of IV compounding Today s hospital pharmacy personnel face multiple interconnected challenges: Improving
More informationData collection in the field
6 Data collection in the field This chapter describes procedures for data collection in the field, i.e. at medicine outlets. Public procurement price data are generally gathered centrally at a government
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationClinical Research at MSU
Financial Administration Development Program: Clinical Research at MSU Kristen Burt, Office of Regulatory Affairs (ORA) Sharon Schooley, Clinical & Translational Sciences Institute (CTSI) February 24,
More informationGOOD CLINICAL PRACTICE (GCP) Series Catalog
GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational
More informationSTATE OF NORTH CAROLINA
STATE OF NORTH CAROLINA PERFORMANCE AUDIT DIVISION OF PRISONS CENTRAL PHARMACY INVENTORY DECEMBER 2009 OFFICE OF THE STATE AUDITOR BETH A. WOOD, CPA STATE AUDITOR PERFORMANCE AUDIT DIVISION OF PRISONS
More informationREGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts
REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationBarcodes on Unit of Use
Barcodes on Unit of Use 1 What hospitals need Hospitals need medications Ready-to-Administer In Unit-of-Use With Barcode 2 What hospitals need Ready-to-Administer If not, must go through additional pharmacy
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection
Effective date of version: April 01, 2012 Study Start-Up SS 202.00 STANDARD OPERATING PROCEDURE FOR Investigator Selection Approval: Nancy M. Paris, MS, FACHE President and CEO 08 March 2012 (Signature
More informationInvestigator Manual HRP-103
HRP-103 Revised October 04, 2016 Table of Contents 1. Introduction... 3 A. Scope... 3 B. Purpose of this manual... 3 C. Where to get additional information and answers to questions... 3 E. Human Research
More informationVOLUME 4 Good manufacturing practices ANNEX 13 Manufacture of investigational medicinal products JULY 2003
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, F2/BL D(2003) Revision
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationPAI Inspections, Observations and Data Integrity
PAI Inspections, Observations and Data Integrity Krishna Ghosh, Ph.D. Office of Pharmaceutical Quality Office of Process and Facilities Center for Drug Evaluation and Research November, 2017 20 November
More informationFDA Audit Preparation
Duke University Ethics and Compliance Office FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Director, CTQA Agenda External audits Best practices to get ready for audits 2 External Audits
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationCompounding Questions and Answers
Compounding Questions and Answers JANUARY 10, 2011 1. Question: What is a reliable supplier? Answer: Some examples of reliable suppliers are FDA licensed manufacturers, CA Department of Public Health Food
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationThe Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
More informationMicrosphere Brachytherapy Sources and Devices
Microsphere Brachytherapy Sources and Devices REVISED AUGUST 2008 Questions should be directed to: Ashley Tull (240) 888-7129 or Ronald Zelac (301) 415-7635 or MedicalQuestions.Resource@nrc.gov Licensing
More informationGuidelines for Developing Randomization Procedures R03
Guidelines for Developing Randomization Procedures R03 Table of Contents 1. Purpose 2. Objective 3. Process 4. Description of Outputs 5. Field Procedures for a Double Blind Trial Involving the Research
More informationHow Data Managers Support Prospective Research
How Data Managers Support Prospective Research CIBMTR Data Managers Meeting February 20, 2018 Hati Kobusingye & Deborah Mattila Prospective Clinical Research Agenda Background - Prospective Research (RCI
More informationPharmacy. Medication. Checks
Pharmacy Medication Checks Module 2 Table of Contents Section A... 1 A.1 Clinical Medication Order Check... 1 A.2 Final Product and Computer Order Entry Check... 1 Section B... 2 B.1 Documentation of Pharmacy
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationElectronic Prescribing and Medicines Administration Project Overview
Electronic Prescribing and Medicines Administration Project Overview 1. Project Background The purpose of the project is to implement an Electronic Prescribing and Medicines Administration (epma) system
More informationPresentation of Capabilities Reverse Logistics
Presentation of Capabilities Reverse Logistics Woodfield Distribution, LLC v081617 Reverse Logistics About Us Description of Services Reverse Distribution Channels DSCSA/Sustainability About Us WDSrx Woodfield
More informationThe Clinical Investigator Site Audit Process-Driven Good Clinical Practice
The Clinical Investigator Site Audit Process-Driven Good Clinical Practice Terry Winchell* GCP Innovative Dynamics, LLC, 7400 Kansas Ave., Kansas City, Kansas 66111-2639, USA Summary This article describes
More informationIRB Considerations for Investigator-Initiated Research
November 29, 2017 IRB Considerations for Investigator-Initiated Research Robert Romanchuk, BSHS, CIP, CCRC, CCRP IRB Vice Chair, Schulman IRB Introducing advarra.com About Schulman IRB Established in 1983
More informationQuality Assurance in Clinical Trials Introduction
Quality Assurance in Clinical Trials Introduction Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 2012 1 Delphine TEPPE-CROITROU - Catherine CORNU (Hospices Civils de Lyon)
More informationNUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014
NUH PHARMACY CLINICAL TRIALS Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014 Dedicated pharmacy trials staff Lead Pharmacist, Service Co-ordinator Pharmacists: Band 7 and 8a Technicians:
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationBest Practices: Using Lynx Mobile to Maximize Charge Capture in the Infusion Suite
Best Practices: Using Lynx Mobile to Maximize Charge Capture in the Infusion Suite If you need assistance with Lynx Mobile, please call 800.482.6700, option 2, or email msh.techsupport@mckesson.com. Best
More informationClinical Research Overview for New Investigators
Clinical Research Overview for New Investigators For the University of Cincinnati IND/IDE Assistance Program May 2011 Agenda Human Subjects Research Clinical Research Roles Sponsors and Corporate Partners
More informationIn consultation with the Behavioral Research Working Group (BRWG), the Statistical and Data Management Center (SDMC), the Network Laboratory (NL),
1 2 In consultation with the Behavioral Research Working Group (BRWG), the Statistical and Data Management Center (SDMC), the Network Laboratory (NL), and the U.S. National Institute for Allergy and Infectious
More informationConsulted With Post/Committee/Group Date Jane Giles Chief Pharmacist 22/09/2014 Professionally Approved By Dr A Jackson MMSG Chairman s action
Vaccine Policy Storage and Monitoring Type: Policy Register No: 10077 Status: Public Developed in response to: Local Need Contributes to CQC Outcome Number: 9 Consulted With Post/Committee/Group Date Jane
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationMaintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist
Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Agenda How an investigator should prepare and submit
More informationZOLL Document Number: 90E0004 Page 5 of 15 Maintenance of Quality Records
ZOLL Number: 90E0004 Page 5 of 15 1. INTRODUCTION 1.1 Purpose 1.2 Scope The purpose of this document is to provide guidance regarding the identification of a quality record and the documentation practices
More informationWhat is an Investigational Drug? 21CFR312.3(b)
Review of the Investigational Drug and Device Regulations Changes to the RSRB Online Submission System (ROSS) Application for Drugs and Devices Kelley O'Donoghue Donoghue, Director OHSP, MPH, CIP and Tiffany
More informationExternal IRB Review What Does it Mean for Your Institution
External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA
More informationAUDIT STATUS. Continuous Auditing Ideas and Priority Ranking Draft: 8/7/2012
Compliance Identify single day stays and subsequent re-admissions Identify inappropriate unbundling of lab tests Identify frequent use of high risk organizations Match OIG-excluded providers list with
More informationApplicability of US Regulations to Canadian Research
Applicability of US Regulations to Canadian Research Mary Kate Needler Capital District Health Authority Halifax, Nova Scotia, Canada N2 Stakeholder Meeting August 18, 2014 MK s Conventions: 1. US Regulation
More informationClinical Trials Management for Molecular Diagnostics. April 2016
Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective
More informationInvestigator Conflict of Interest Disclosure Policy for Human Subjects Research
55 Fogg Road South Weymouth Massachusetts 02190-2455 Investigator Conflict of Interest Disclosure Policy for Human Subjects Research PURPOSE OF POLICY Financial or other incentives may negatively impact
More informationExpedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014
Expedited Reporting Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Journal of Clinical Research Best Practices Vol. 7, No. 1, January 2011 Can You
More informationGuidance for Industry - Computerized Systems Used in Clinical Trials
Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials
More information5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)
5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationThe Revised Common Rule. Ann Johnson, PhD, MPH IRB Director University of Utah
The Revised Common Rule Ann Johnson, PhD, MPH IRB Director University of Utah Objectives Describe the Changes that Affect the UU IRB What does this mean for ERICA? UPDATE: The postponement to January 2019
More information